Table 2.
Progression-free survival (PFS) and overall survival (OS) patients with metastatic colorectal cancer treated with bevacizumab, grouped according to serum carcinoembryonic antigen (CEA) level
| PFS in CEA populations | ||
|---|---|---|
| Median survival, months | Bevacizumab | |
| CEA ≤26.8 ng/mL | 8.5 months | |
| CEA >26.8 ng/mL | 6.4 months | |
| P-value in group | 0.023 | |
| Survival rate in per cent (95% CI) | CEA≤26.8 ng/mL | CEA >26.8 ng/mL |
| 3 months | 89 (83–96) | 76 (68–86) |
| 6 months | 68 (59–79) | 54 (44–67) |
| 9 months | 47 (37–60) | 27 (19–40) |
| 12 months | 24 (15–36) | 13 (7–25) |
| T stage, hazard ratio (95% CI) | 0.89 (0.66–1.22) | |
| P = 0.465 | ||
| N stage, hazard ratio (95% CI) | 1.18 (0.85–1.62) | |
| P = 0.325 | ||
| OS in CEA populations | ||
|---|---|---|
| Median survival, months | Bevacizumab | |
| CEA ≤26.8 ng/mL | 37.5 months | |
| CEA >26.8 ng/mL | 21.4 months | |
| P-value in group | 0.019 | |
| Survival rate in per cent (95% CI) | CEA ≤26.8 ng/mL | CEA >26.8 ng/mL |
| 6 months | 92 (86–98) | 89 (82–96) |
| 12 months | 81 (73–90) | 68 (58–79) |
| 18 months | 69 (59–81) | 57 (47–70) |
| 24 months | 62 (51–75) | 43 (32–58) |
| T stage, hazard ratio (95% CI) | 1.05 (0.70–1.58) | |
| P = 0.803 | ||
| N stage, hazard ratio (95% CI) | 1.46 (0.97–2.20) | |
| P = 0.068 | ||
Median time and survival rates are based on Kaplan–Meier estimates. CI, confidence interval.